Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

FDA Panel Votes Proposed Olaparib/Abiraterone Indication Should Be Restricted to BRCA-Mutant mCRPC

April 28th 2023

In an 11-to-1 vote, the FDA’s Oncologic Drugs Advisory Committee voted that the proposed indication of olaparib in combination with abiraterone acetate and prednisone or prednisolone for the initial treatment of patients with metastatic castration-resistant prostate cancer should be restricted to those whose tumors harbor a BRCA mutation.

Dr Liu on PSMA PET Imaging in Prostate Cancer

April 28th 2023

Jen-Jane Liu, MD, discusses the benefits of using prostate-specific membrane antigen PET imaging in the localized disease setting for patients with prostate cancer, the differences between PSMA PET and conventional imaging, and future considerations for effectively implementing this diagnostic approach in this population.

Frontline Olaparib Plus Abiraterone Reduces PSA Levels, Delays Time to PSA Progression in mCRPC

April 28th 2023

The addition of olaparib to abiraterone acetate resulted in numerically higher prostate-specific antigen response rates and prolonged time to PSA progression vs abiraterone alone when used in the frontline treatment of patients with metastatic castration-resistant prostate cancer.

Extended Darolutamide Demonstrates Long-term Safety, Clinical Benefit in Nonmetastatic CRPC

April 28th 2023

Darolutamide given in an extended duration was linked with long-term clinical benefit and safety in patients with nonmetastatic castration-resistant prostate cancer.

177Lu-PSMA-I&T Generates PSA Responses With Tolerable Safety in mCRPC

April 28th 2023

Treatment with lutetium 177 PSMA-I&T radioligand therapy led to prostate-specific antigen declines with an acceptable toxicity profile in patients with metastatic castration-resistant prostate cancer.

Dr Aggarwal on the Activity of BXCL701 Plus Pembrolizumab in SCNC mCRPC

April 26th 2023

Rahul Aggarwal, MD, discusses key findings from a phase 2a trial evaluating the combination of BXCL701 and pembrolizumab in patients with metastatic castration-resistant prostate cancer with the small cell neuroendocrine cancer phenotype.

Nasr on the Need for Preclinical Models of Prostate Cancer Dormancy

April 26th 2023

Mostafa Nasr, PhD candidate, discusses the development of novel preclinical models of prostate cancer dormancy, and the significance of these outcomes may have on future research in metastatic prostate cancer.

Treatment Approaches for Patients with mCRPC and Bone-Only Disease Progression After Radiotherapy

April 26th 2023

Drs Manning and Armstrong discuss the best treatment approaches for a patient with mCRPC and disease progression in the bone after initial radiotherapy for metastatic disease.

Patient Profile: A 78-Year-Old Man with mCRPC

April 26th 2023

Dr Andrew Armstrong presents a profile of a 78-year-old man with mCRPC with a single PSMA-avid bone metastasis and asks Dr Manning how he would treat the patient in question.

Metastatic Hormone-Sensitive Prostate Cancer: Data From ARASENS and ARANOTE

April 26th 2023

A panel of medical oncologist reflect on clinical data from the ARASENS and ARANOTE trials utilizing combination strategies with darolutamide in mHSPC.

mHSPC: Use of Triplet Therapy

April 26th 2023

Experts in prostate cancer consider patient suitability for triplet therapy in the setting of metastatic hormone-sensitive disease.

FDA Grants Fast Track Designation to 177Lu-PNT2002 for mCRPC

April 25th 2023

The FDA has granted a fast track designation to 177Lu-PNT2002 for the treatment of patients with metastatic castration-resistant prostate cancer.

Niraparib/Abiraterone Acetate Combo Approved in Europe for BRCA1/2+ mCRPC

April 24th 2023

The European Commission has granted marketing authorization to the dual action tablet comprised of niraparib and abiraterone acetate to be administered with prednisone or prednisolone in adult patients with BRCA1/2-mutated metastatic castration-resistant prostate cancer in whom chemotherapy is not clinically indicated.

Factors in Selecting Therapy for Patients With Metastatic Hormone-Sensitive Prostate Cancer

April 19th 2023

A focused review of patient and disease factors that inform selection of therapy for patients with metastatic hormone-sensitive prostate cancer.

Treatment Goals for Patients With Metastatic Hormone-Sensitive Prostate Cancer

April 19th 2023

Centering discussion on metastatic hormone-sensitive prostate cancer (mHSPC), key opinion leaders identify core goals of treatment.

CYCLONE 1 Misses Primary End Point But Abemaciclib Shows Activity in mCRPC

April 18th 2023

Although the phase 2 CYCLONE 1 trial did not meet its primary end point of overall response rate, treatment with abemaciclib did demonstrate clinical activity among patients with metastatic castration-resistant prostate cancer.

Approved Treatment Options for Patients with mCRPC

April 17th 2023

Medical oncologist Andrew Armstrong, MD, details the available treatment options for patients with mCRPC, and how recommendations vary by prior therapy and mutation status.

The Evolution of Treatment Paradigms in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

April 17th 2023

Andrew Armstrong, MD, and Matthew Manning, MD, explain how the treatment options and typical patient outcomes in mCRPC have changed over history.

Optimizing Care for Patients With Non-metastatic CRPC

April 12th 2023

Before shifting focus away from non-metastatic castration-resistant prostate cancer, medical oncologists reflect on means to optimize care and look to future directions in the field.

Non-metastatic Castration-Resistant Prostate Cancer: Patient Monitoring Strategies

April 12th 2023

Experts on non-metastatic castration-resistant prostate cancer share insight on patient monitoring strategies to improve outcomes.